Abstract: An adhesive composition contains at least a polymer and an ionic liquid. The adhesive composition includes components such that when an ionic liquid-free adhesive layer is formed of a composition composed of the components of the adhesive composition that are other than the ionic liquid among components contained in the adhesive composition, the ionic liquid-free adhesive layer has a relative permittivity of 5 or more at a frequency of 100 Hz, after being left to stand in an environment of 22° C. and 20% RH for 3 days.

Abstract: A method for synthesizing a purified lithium (Li)+ anion binding agent (ABA-F)? salt and the corresponding Li+(ABA-F)? are disclosed. The method includes dissolving a boron-based acid in a polar solvent to form a solution. The solution is refluxed to form an anion binding agent. A stoichiometric amount of a small fluorinated salt, such as LiF, is added to the anion binding agent to form a mixture. The mixture is subsequently crystallized to obtain a substantially pure Li+(ABA-F)? salt. Example purified Li+(ABA-F)? salts include Ox-Li+(ABA-F), m-Li+(ABA-F), and BF3—Li+(ABA-F)?. These purified Li+(ABA-F)? salts provide the benefits of increased battery thermal safety without loss of electrochemical performance.

Abstract: The present invention relates to a new process for the preparation of 6-hydroxy-5-arylbicyclo[2.2.2]octan-2-one compounds of the formula (II); which may subsequently be further transformed to compounds of the formula (I): The present invention further relates to novel compounds as such, which compounds are useful intermediates in the above process.

Abstract: A radiation-sensitive composition includes a compound represented by a formula (1), and a polymer having a structural unit that includes an acid-labile group. In the formula (1), R1 represents a group having a polar group; n is an integer of 1 to 4, wherein, in a case where R1 is present in a plurality of number, the plurality of R1s are identical or different, and optionally at least two R1s taken together represent a cyclic structure; A represents an alicyclic hydrocarbon group having a valency of (n+1); and M+ represents a monovalent onium cation.

Abstract: The invention relates to a process for preparing an internal olefin sulfonate, comprising sulfonating an internal olefin, having an average carbon number that is equal to or greater than 20, in a sulfonation reactor into sulfonated internal olefin followed by contacting sulfonated internal olefin with a base containing solution, wherein the sulfonation reactor is cooled with a cooling means having a temperature which is greater than 35° C. Further, the invention relates to an internal olefin sulfonate obtainable by said process, and to use of internal olefin sulfonates obtainable or obtained by said process as a surfactant, suitably as a surfactant in chemical Enhanced Oil Recovery.

Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Abstract: The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.

Abstract: Methods for preparing phosphonium salts by reacting a primary phosphine or a secondary phosphine with an ester compound selected from the group consisting of: a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester; to form a phosphonium salt of formula VII wherein each of RQ, RX, RY, and RZ is independently hydrocarbyl and X? is a phosphate, phosphonate, sulfate, or sulfonate are provided herein. These phosphonium salts may find utility in a wide range of applications, including as surfactants, as polar solvents (ionic liquids), as antimicrobial agents, and as a component of spinning finish in polyamide fiber processing.

Abstract: The present invention relates to a new process for the diastereoselective preparation of (1R*,4R*,5S*,6S*)-6-hydroxy-5-arylbicyclo[2.2.2]octan-2-one compounds, the compounds of the formula (II), which may subsequently be further transformed to 5-aryl-bicyclo[2.2.2]oct-5-en-2-one compounds of the formula (I): The present invention further relates to novel (1R*,2S*,3S*,4R*)-6-oxo-3-arylbicyclo[2.2.2]octan-2-yl methanesulfonate compounds as such, which compounds are useful intermediates in the preparation of 5-aryl-bicyclo[2.2.2]oct-5-en-2-one compounds of the formula (I).

Abstract: The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH2, O, S, S(O) or S(O)2; R1 represents a hydrogen atom or a methyl group; R2 and R3 represents a hydrogen atom, a C1-6 alkyl group and the like; R4 represents a C6-10 aryl group or a five- to six-membered heteroaryl group; G represents a hydrogen atom and the like; Z represents a halogen atom, a cyano group, a nitro group, a phenyl group, a C1-6 alkyl group and the like; is useful as an active ingredient for herbicides.

Abstract: The present invention provides electrophilic alkylating reagents of formula II, wherein is an aryl group, R2 is an alkyl group, R3 is a substituted phenyl group, wherein the number of substituents (n) is greater than 2 and R4 is an anion, and salts thereof, methods for their preparation and methods for the preparation of alkylated biologically active compounds using such reagents.

Abstract: The present invention relates to a (2R, 3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process.

Abstract: Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.

Abstract: The present invention relates to a new process for the diastereoselective preparation of (1R*,4R*,5S*,6S*)-6-hydroxy-5-arylbicyclo[2.2.2]octan-2-one compounds, the compounds of the formula (II), which may subsequently be further transformed to 5-aryl-bicyclo[2.2.2]oct-5-en-2-one compounds of the formula (I): The present invention further relates to novel (1R*,2S*,3S*,4R*)-6-oxo-3-arylbicyclo[2.2.2]octan-2-yl methanesulfonate compounds as such, which compounds are useful intermediates in the preparation of 5-aryl-bicyclo[2.2.2]oct-5-en-2-one compounds of the formula (I).

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: The disclosed subject matter relate to a di-tert-butylphenyl alkylsulfonate compound, tert-butylphenyl alkylsulfonate compound, di-tert-butylphenyl arylsulfonate compound or tert-butylphenyl arylsulfonate compound useful as an intermediate raw material of a pharmaceutical, agricultural chemical, electronic material or polymer material and the like, or as a battery material, and also provides a nonaqueous electrolytic solution for a lithium secondary battery having superior cycle performance and other battery properties through the use thereof, and a lithium secondary battery. The disclosed embodiments further relate to a nonaqueous electrolytic solution for use as in a lithium secondary battery containing, in a nonaqueous electrolytic solution in which an electrolyte salt is dissolved in a nonaqueous solvent, 0.

Abstract: A composition is disclosed comprising an oily medium and at least one compound represented by the following formula (Z) A-L-[D1-(E)q-D2-(B)m—Z1—R]p??(Z) wherein A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents a carbonyl group or a sulfonyl group; D2 represents a carbonyl group, a sulfonyl group, a carboxyl group, a sulfonyloxyl group, a carbamoyl group, or a sulfamoyl group; E represents a divalent group; R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group; B represents an oxyethylene group or the like; and Z1 represents a single bond or a divalent group.

Abstract: The present invention is directed towards novel sulfonic acid esters as catalysts for crosslinking of polymers having hydroxyl, carboxyl, and amide functional groups with a crosslinking agent and resin compositions containing the same. The present invention provides polymeric film coatings which have superior hardness, impact resistance, adhesion, improved blister resistance, salt spray characteristics and flexibility. These catalysts are especially effective in coil primer formulations containing calcium ion exchange anticorrosive pigments, where traditional blocked acid catalysts are ineffective.

Abstract: The present invention relates to a new process for the preparation of 6-hydroxy-5-arylbicyclo[2.2.2]octan-2-one compounds of the formula (II); which may subsequently be further transformed to compounds of the formula (I): The present invention further relates to novel compounds as such, which compounds are useful intermediates in the above process.

Abstract: There are disclosed sulfonic acid precursor compositions, as are methods of using these compositions in, for example, photolithography. Other embodiments are also disclosed.

Abstract: The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

Abstract: A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: Provided herein are geranylgeranylacetone derivatives and methods of using them.

Abstract: A method is disclosed for manufacturing surfactants for utilization in petroleum industry operations. The method comprises providing a bio-lipid. The bio-lipid can include one or more medium-chain or long-chain fatty acids, such as Lauric acid, Myristic acid, Palmitic acid, Stearic acid, Palmitoleic acid, Oleic acid, Ricinoleic acid, Vaccenic acid, Linoleic acid, Alpha-Linoleic acid, or Gamma-Linolenic acid. Fatty acid alkyl esters are produced by reacting the bio-lipid with a low-molecular weight alcohol. The fatty acid alkyl esters are reduced to a fatty alcohol. The fatty alcohol is dimerized to form a Guerbet alcohol, which is a precursor to producing surfactant for utilization in a petroleum industry operation, such as an enhanced oil recovery process.

Abstract: A sulfonium salt has formula (1) wherein R1 is a monovalent hydrocarbon group except vinyl and isopropenyl, R2, R3, and R4 are alkyl, alkenyl, oxoalkyl, aryl, aralkyl or aryloxoalkyl or may bond together to form a ring with the sulfur atom, and n is 1 to 3. A chemically amplified resist composition comprising the sulfonium salt is capable of forming a fine feature pattern of good profile after development due to high resolution, improved focal latitude, and minimized line width variation and profile degradation upon prolonged PED.

Abstract: The invention relates to a process for the synthesis of (Z)-3-[2-butoxy-3?-(3-heptyl-1-methylureido)biphenyl-4-yl]-2-methoxyacrylic acid of formula (I): and also to the process for the synthesis of the reaction intermediates of general formula (XII), and to the said compounds when R2 is chosen from the methyl, trifluoromethyl, phenyl and 4-tolyl radicals:

Abstract: Disclosed is an electrolyte comprising a compound having both a sulfonate group and a cyclic carbonate group. The electrolyte forms a more stable and dense SEI layer on the surface of an anode, and thus improves the capacity maintenance characteristics and lifespan characteristics of a battery. Also, disclosed is a compound represented by the following Formula 1, and a method for preparing the same by reacting 4-(hydroxyalkyl)-1,3-dioxolan-2-one with a sulfonyl halide compound: wherein each of R1 and R2 independently represents a C1˜C6 alkylene group optionally containing a C1˜C6 alkyl group or C2˜C6 alkenyl group introduced thereto; R3 is selected from the group consisting of a hydrogen atom, C1˜C20 alkyl group, C3˜C8 cyclic alkyl group, C2˜C6 alkenyl group, halo-substituted alkyl group, phenyl group and benzyl group.

Abstract: There are provided: a proton transporting material that improves mechanical characteristics of a sulfonated liquid crystalline polymer material, can be kept as a membrane even though it is made a solid state while maintaining a molecular arrangement of a liquid crystalline state, and is suitable for electrolyte membranes of fuel cells etc.; an ion exchange membrane, a membrane electrolyte assembly (MEA), and a fuel cell that use the proton transporting material; a starting material for the proton transporting material. The proton transporting material has a molecular structure produced by crosslinking the sulfonated liquid crystalline polymer material with a crosslinking agent having two or more functional groups in sites except that of the sulfonic acid group.

Abstract: Provided is a photoresist that includes a polymer is free of a aromatic group and a photo acid generator (PAG) that has less than three aromatic groups. In an embodiment, the PAG includes an anion component and a cation component. The anion component has one of the following chemical formulas: R31C—CR21—CR21—CR21—SO3? R31C—CR21—CR21—SO3? R31C—CR21—SO3? R31C—SO3? The cation component has one of the following chemical formulas: Wherein R1 and R2 each represent a chemical compound.

Abstract: The present invention describes the method of making anionic ether sulfate surfactants by alkoxylation of a GA using PO and/or EO followed by a sulfation reaction. The GA of the present invention is made by a facile and inexpensive method that involves high temperature base catalyzed dimerization of a linear alcohol. The ether sulfate surfactants of the present invention find uses in EOR applications where it is used for solubilization and mobilization of oil and for environmental cleanup.

Abstract: The present invention concerns the use of dibutyl tin oxide for regioselective catalytic diol mono-tosylation at a concentration lower than 2 mol %. The present invention also concerns the use of a generic acetal compound of Formula (Ic) in a catalytic process for regioselective diol mono-tosylation, wherein Y is selected from the group of C1-6alkyl, phenyl and benzyl. The concentration of the generic acetal compound of Formula (Ic) is less than about 2 mol %, preferably ranges between about 2 mol % and about 0.0005 mol %, preferably ranges between about 0.1 mol % and about 0.005 mol %.

Abstract: Demulsifiers containing an anionic surfactant selected from alkylsulfosuccinates, alkylsulfonates, alkylphosphonic acids, and their salts; a nonionic surfactant selected from ethylene oxide/propylene oxide copolymers, ethoxylated fatty acids of polyethylene glycol, terpene alkoxylates, and modified alkanolamides; or a combination of an anionic and a nonionic surfactant, and methods of use thereof in breaking emulsions.

Abstract: A detergent composition comprising an esterified substituted benzene sulfonate, a hydrogen peroxide source, a soil suspending polymer, and an organic catalyst.

Abstract: The present invention relates to a novel method for the preparation of diol intermediates having the formula (II) and/or the opposite enantiomer of an acylated diol having the formula (IV) useful for the preparation of escitalopram involving selective enzymatic acylation or deacylation.

Abstract: A method of producing a modified pigment by sulfonating a pigment and subsequently oxidizing the pigment. The modified pigment may have sulfonic acid and carboxyl surface modifying groups attached to the surface of the pigment. Charge balancing counterions such as alkali metals, alkaline earth metals and NR1R2R3H+, where R1, R2 and R3 are independently H or C1-C5 alkyl groups, may be associated with the surface modifying groups. The modified pigment is combined with water to produce a dispersion that can be used in such applications as coatings, paints, papers, adhesives, latexes, toners, textiles, fibers, plastics and inks.

Abstract: Compounds represented by the following structural formulas can be used as photoacid generators: Such compounds are useful, for example, in fabricating arrays of polymers.

Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.

Abstract: The invention relates to a new process for the preparation of N-[3-[(2-methoxyphenyl)sulfanyl]-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine.

Abstract: A method and a device for the sulfonation or the sulfation of organic liquid raw materials with an SO3/air mixture and other reaction gases in order to perform rapid, highly exothermic gas-liquid reactions in conventional thin-layer falling-film reactors are disclosed. The introduction of the SO3/air mixture occurs through several feed locations, which are located within (along) the reaction tube or reaction tubes or in the annular gap of annular-gap falling-film reactors. High peak temperatures, undesirable byproducts, worsening of the color and local oversulfation or oversulfonation, which leads to side reactions, are largely avoided.

Abstract: The present invention relates to the use of a compound of Formula (I??) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.

Abstract: The invention is directed to a method for preparing sulfated psyllium derivatives for use to reduce the risk of chronic human diseases. The sulfation of psyllium was carried out with sulfur, trioxide, pyridine, dimethylformamide and chlorosulfonic acid in pyridine. Six total sulfated psyllium derivatives named SP1, SP2, SP3, SPR1, SPR2, and SPR3 were prepared and evaluated for their morphological and rheological properties, and bile acid-binding abilities. The invention offers a novel approach to obtaining sulfated psyllium derivatives for use in functional foods or supplemental and pharmaceutical products to increase health benefits.

Abstract: An agglomerated particulate lignosulfonate material may be made by introducing or forming lignosulfonate microparticles in a fluidized bed agglomerator, and introducing sufficient heated gas and lignosulfonate liquid in the agglomerator to convert the microparticles to lignosulfonate granules of enlarged size. The granules may have an average size of at least 0.1 mm, and may be used to make a dry-blended cement additive or oil well cement that may be dustless, easily poured and stored, and rapidly dissolved in water.

Abstract: Activated Supports, support-bound activators, strongly acidic supports, and silylating supports are provided; the activated support having the formula: wherein L is a linking group component; X is F, Cl, OH, and trisubstituted silyloxy; and the shaded circle represents a solid or semi-solid support. Methods of using the activated supports in solid phase organic synthesis are also provided.

Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.

Abstract: A prepolymer and products made from the preopolymer is described. The prepolymer includes the reaction product of at least one isocyanate and at least one natural oil based polyol. The natural oil based polyol includes at least two natural oil moieties separated by a molecular structure having an average of at least about 19 ether groups between any 2 of the natural oil moieties or by a polyether molecular structure having an equivalent weight of at least about 480.

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: The invention relates to a process for the synthesis of (Z)-3-[2-butoxy-3?-(3-heptyl-1-methylureido)biphenyl-4-yl]-2-methoxyacrylic acid of formula (I): and also to the process for the synthesis of the reaction intermediates of general formula (XII), and to the said compounds when R2 is chosen from the methyl, trifluoromethyl, phenyl and 4-tolyl radicals:

Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.